Here’s what one investment analyst told investors about President Trump’s drug pricing proposals: “Obviously, very, very positive to pharma. Essentially, we are not seeing anything about that speech which should concern investors.”https://www.washingtonpost.com/business/economy/trump-promises-to-derail-gravy-train-and-lower-drug-prices-in-american-patients-first-plan/2018/05/11/6e38af06-5532-11e8-a551-5b648abe29ef_story.html?utm_term=.a9df109146c6 …
